June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Influence of Vitreomacular Interface Configuration on Anti-vascular Endothelial Growth Factor Treatment for Neovascular Age-related Macular Degeneration: A Meta-analysis
Author Affiliations & Notes
  • Meng Gao
    Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing, Beijing, China
  • Wu Liu
    Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing, Beijing, China
  • XiDa Liang
    Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing, Beijing, China
  • YanPin Yu
    Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing, Beijing, China
  • Footnotes
    Commercial Relationships   Meng Gao, None; Wu Liu, None; XiDa Liang, None; YanPin Yu, None
  • Footnotes
    Support  National Nature Science Foundation of China (No.81541106)
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 884. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Meng Gao, Wu Liu, XiDa Liang, YanPin Yu; Influence of Vitreomacular Interface Configuration on Anti-vascular Endothelial Growth Factor Treatment for Neovascular Age-related Macular Degeneration: A Meta-analysis. Invest. Ophthalmol. Vis. Sci. 2017;58(8):884.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the influence of vitreomacular interface configuration on treatment outcomes after intravitreal anti-vascualr endothelial growth factor (anti-VEGF) therapy for exudative age-related macular degeneration (AMD).

Methods : The Pubmed, EMBASE and Cochrane Central Register of Controlled Trials databases were searched to identify relevant prospective or retrospective studies that evaluate the influence of vitreomacular adhesion (VMA) or vitreomacular traction (VMT) on functional and anatomical outcomes in neovascular AMD patients treated with anti-VEGF agents. The outcome measures were the mean change in best corrected visual acuity (BCVA) from baseline, the mean change in central macular thickness (CMT) from baseline and the mean injection numbers of anti-VEGF treatment from baseline.

Results : Ten studies were selected for this meta-analysis, including 2249 eyes (434 eyes in VMA/VMT group and 1815 eyes in non-VMA/VMT group). In neovascular AMD patients treated with anti-VEGF agents, VMA/VMT group was associated with poorer visual acuity gains and CMT reductions (mean difference [MD] =-5.32, 95% confidence interval [CI] = -10.17 to -0.47, P=0.03; mean difference [MD] =21.04, 95% confidence interval [CI] = 2.22 to 39.86, P=0.03, respectively). There was no significant difference in the mean injection numbers between two groups at 1 year (mean difference [MD] =0.17, 95% confidence interval [CI] = -0.42 to 0.75, P=0.57), whereas VMA/VMT group had a significantly higher mean injection numbers over 2 years or more (mean difference [MD] =0.74, 95% confidence interval [CI] = -0.02 to 1.45, P=0.04).

Conclusions : The limited evidence suggests that vitreomacular interface configuration have a significant influence on the visual outcomes, CMT reduction and long-term injection numbers in neovascular AMD patients treated with anti-VEGF agents. However, the results of this meta-analysis should be interpreted with caution because of the heterogeneity among study designs. Eyes with VMA/VMT on optical coherence tomography at baseline may require more intensive treatment with decreased response to anti-VEGF agents.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×